PAFAH1B3

Summary

PAFAH1B3 (platelet activating factor acetylhydrolase 1b catalytic subunit 3, HGNC:8576) is a protein-coding gene on chromosome 19q13.1, encoding Platelet-activating factor acetylhydrolase IB subunit alpha1 (Q15102). Alpha1 catalytic subunit of the cytosolic type I platelet-activating factor (PAF) acetylhydrolase (PAF-AH (I)) heterotetrameric enzyme that catalyzes the hydrolyze of the acetyl group at the sn-2 position of PAF and its analogs and modulates the action of PAF.

This gene encodes an acetylhydrolase that catalyzes the removal of an acetyl group from the glycerol backbone of platelet-activating factor. The encoded enzyme is a subunit of the platelet-activating factor acetylhydrolase isoform 1B complex, which consists of the catalytic beta and gamma subunits and the regulatory alpha subunit. This complex functions in brain development. A translocation between this gene on chromosome 19 and the CDC-like kinase 2 gene on chromosome 1 has been observed, and was associated with cognitive disability, ataxia, and atrophy of the brain. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 5050 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 45 total
• Druggable target: yes
• MANE Select transcript: NM_002573

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8576
Approved symbol	PAFAH1B3
Name	platelet activating factor acetylhydrolase 1b catalytic subunit 3
Location	19q13.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000079462
Ensembl biotype	protein_coding
OMIM	603074
Entrez	5050

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 17 protein_coding, 1 retained_intron

ENST00000262890, ENST00000538771, ENST00000594989, ENST00000595530, ENST00000596265, ENST00000597333, ENST00000599778, ENST00000601865, ENST00000877854, ENST00000877855, ENST00000877856, ENST00000916656, ENST00000916657, ENST00000916658, ENST00000916659, ENST00000916660, ENST00000916661, ENST00000916662

RefSeq mRNA: 3 — MANE Select: NM_002573 NM_001145939, NM_001145940, NM_002573

CCDS: CCDS12602

Canonical transcript exons

ENST00000262890 — 5 exons

Exon	Start	End
ENSE00000709342	42299970	42300092
ENSE00000897478	42302232	42302624
ENSE00003566592	42301950	42302039
ENSE00003785459	42300171	42300287
ENSE00003909693	42297035	42297365

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 99.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.1591 / max 355.4254, expressed in 1795 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181176	9.8995	1590
181174	8.5434	1586
181179	3.3557	1446
181171	2.9530	829
181172	2.8497	1023
181173	2.1759	920
181177	1.5626	885
181175	0.9165	542
181178	0.9028	616

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.32	gold quality
ganglionic eminence	UBERON:0004023	98.99	gold quality
ventricular zone	UBERON:0003053	97.99	gold quality
embryo	UBERON:0000922	97.01	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	95.63	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.86	gold quality
cerebellar hemisphere	UBERON:0002245	93.82	gold quality
cerebellar cortex	UBERON:0002129	93.76	gold quality
cerebellum	UBERON:0002037	91.89	gold quality
mucosa of transverse colon	UBERON:0004991	89.39	gold quality
nucleus accumbens	UBERON:0001882	89.04	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.98	gold quality
prefrontal cortex	UBERON:0000451	88.95	gold quality
right adrenal gland	UBERON:0001233	88.82	gold quality
amygdala	UBERON:0001876	88.75	gold quality
right frontal lobe	UBERON:0002810	88.54	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.48	gold quality
caudate nucleus	UBERON:0001873	88.30	gold quality
cingulate cortex	UBERON:0003027	88.09	gold quality
right adrenal gland cortex	UBERON:0035827	88.07	gold quality
anterior cingulate cortex	UBERON:0009835	87.89	gold quality
endometrium epithelium	UBERON:0004811	87.72	gold quality
esophagus mucosa	UBERON:0002469	87.34	gold quality
hypothalamus	UBERON:0001898	87.10	gold quality
putamen	UBERON:0001874	87.08	gold quality
left adrenal gland	UBERON:0001234	86.93	gold quality
left adrenal gland cortex	UBERON:0035825	86.88	gold quality
lower esophagus mucosa	UBERON:0035834	86.47	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.45	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	86.38	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	998.15
E-HCAD-5	yes	42.81
E-GEOD-134144	yes	29.78
E-GEOD-125970	yes	16.88
E-ANND-3	yes	7.27
E-CURD-114	yes	6.87
E-GEOD-93593	no	574.81

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 8)

• These results indicate an antagonistic effect of alpha1, alpha2 and Ndel1 for Lis1 binding, probably to modulate dynein functions in vivo. (PMID:19622634)
• intracellular type I PAF acetylhydrolase (PAFAH1B2 and PAFAH1B3) is the major aspirin hydrolase of human blood (PMID:21844189)
• PAFAH1B3 has been found to be differentially methylated in head and neck squamous cell carcinoma. (PMID:22461910)
• PAFAH1B3 as a critical metabolic node in breast cancer (PMID:24954006)
• PAFAH1B2 and 1B3 are important in maintaining cancer pathogenicity across a wide spectrum of cancer types. (PMID:25945974)
• [Correlation between PAFAH1B3 Expression Level and Risk of Disease Progression After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients]. (PMID:37096518)
• PAFAH1B3 Regulates Papillary Thyroid Carcinoma Cell Proliferation and Metastasis by Affecting the EMT. (PMID:37102492)
• PAFAH1B3 is a KLF9 target gene that promotes proliferation and metastasis in pancreatic cancer. (PMID:38649699)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pafah1b3	ENSMUSG00000005447
rattus_norvegicus	Pafah1b3	ENSRNOG00000020481
drosophila_melanogaster	Paf-AHalpha	FBGN0025809

Paralogs (2): ICE1 (ENSG00000164151), PAFAH1B2 (ENSG00000168092)

Protein

Protein identifiers

Platelet-activating factor acetylhydrolase IB subunit alpha1 — Q15102 (reviewed: Q15102)

Alternative names: PAF acetylhydrolase 29 kDa subunit, PAF-AH subunit gamma

All UniProt accessions (7): Q15102, A0A024R0L6, M0QXS6, M0QZT2, M0R1K3, M0R323, M0R389

UniProt curated annotations — full annotation on UniProt →

Function. Alpha1 catalytic subunit of the cytosolic type I platelet-activating factor (PAF) acetylhydrolase (PAF-AH (I)) heterotetrameric enzyme that catalyzes the hydrolyze of the acetyl group at the sn-2 position of PAF and its analogs and modulates the action of PAF. The activity and substrate specificity of PAF-AH (I) are affected by its subunit composition. Both alpha1/alpha1 homodimer (PAFAH1B3/PAFAH1B3 homodimer) and alpha1/alpha2 heterodimer(PAFAH1B3/PAFAH1B2 heterodimer) hydrolyze 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoric acid (AAGPA) more efficiently than PAF, but they have little hydrolytic activity towards 1-O-alkyl-2-acetyl-sn-glycero-3-phosphorylethanolamine (AAGPE). Plays an important role during the development of brain.

Subunit / interactions. Forms a catalytic dimer which is either homodimer (alpha1/alpha1 homodimer) or heterodimer with PAFAH1B2 (alpha1/alpha2 heterodimer). Component of the cytosolic (PAF-AH (I)) heterotetrameric enzyme, which is composed of PAFAH1B1 (beta), PAFAH1B2 (alpha2) and PAFAH1B3 (alpha1) subunits. The catalytic activity of the enzyme resides in the alpha1 (PAFAH1B3) and alpha2 (PAFAH1B2) subunits, whereas the beta subunit (PAFAH1B1) has regulatory activity. Trimer formation is not essential for the catalytic activity. Interacts with VLDLR; this interaction may modulate the Reelin pathway.

Subcellular location. Cytoplasm.

Tissue specificity. In the adult, expressed in brain, skeletal muscle, kidney, thymus, spleen, colon, testis, ovary and peripheral blood leukocytes. In the fetus, highest expression occurs in brain.

Activity regulation. Beta subunit (PAFAH1B1) inhibits the acetylhydrolase activity of the alpha1/alpha1 catalytic homodimer.

Miscellaneous. Originally the subunits of the type I platelet-activating factor (PAF) acetylhydrolase was named alpha (PAFAH1B1), beta (PAFAH1B2) and gamma (PAFAH1B3). Now these subunits have been renamed beta (PAFAH1B1), alpha2 (PAFAH1B2) and alpha1 (PAFAH1B3) respectively.

Similarity. Belongs to the ‘GDSL’ lipolytic enzyme family. Platelet-activating factor acetylhydrolase IB beta/gamma subunits subfamily.

RefSeq proteins (3): NP_001139411, NP_001139412, NP_002564* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013830	SGNH_hydro	Domain
IPR036514	SGNH_hydro_sf	Homologous_superfamily

Pfam: PF13472

Catalyzed reactions (Rhea), 3 shown:

• a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = a 1-O-alkyl-sn-glycero-3-phosphocholine + acetate + H(+) (RHEA:17777)
• 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O-hexadecyl-sn-glycero-3-phosphocholine + acetate + H(+) (RHEA:40479)
• 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphate + H2O = 1-O-hexadecyl-sn-glycero-3-phosphate + acetate + H(+) (RHEA:41704)

UniProt features (8 total): active site 3, modified residue 2, initiator methionine 1, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15102-F1	95.20	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 47; 192; 195

Post-translational modifications (2): 2, 2

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6811436	COPI-independent Golgi-to-ER retrograde traffic

MSigDB gene sets: 223 (showing top): RNGTGGGC_UNKNOWN, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, HNF3ALPHA_Q6, SWEET_KRAS_ONCOGENIC_SIGNATURE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, KYNG_DNA_DAMAGE_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_MALE_GAMETE_GENERATION, REACTOME_MEMBRANE_TRAFFICKING, NFKB_Q6, PATIL_LIVER_CANCER, PUJANA_CHEK2_PCC_NETWORK, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, MODULE_118

GO Biological Process (4): lipid metabolic process (GO:0006629), spermatogenesis (GO:0007283), nervous system development (GO:0007399), lipid catabolic process (GO:0016042)

GO Molecular Function (8): 1-alkyl-2-acetylglycerophosphocholine esterase activity (GO:0003847), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), protein-containing complex binding (GO:0044877), protein heterodimerization activity (GO:0046982), platelet-activating factor acetyltransferase activity (GO:0047179), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), 1-alkyl-2-acetylglycerophosphocholine esterase complex (GO:0008247), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Golgi-to-ER retrograde transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein dimerization activity	2
binding	2
primary metabolic process	1
developmental process involved in reproduction	1
male gamete generation	1
system development	1
lipid metabolic process	1
catabolic process	1
carboxylic ester hydrolase activity	1
protein binding	1
identical protein binding	1
acetyltransferase activity	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
catalytic complex	1

Protein interactions and networks

STRING

1046 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PAFAH1B3	PAFAH1B1	P43034	940
PAFAH1B3	PAFAH1B2	P68402	807
PAFAH1B3	CLK2	P49760	770
PAFAH1B3	KIF1A	Q12756	688
PAFAH1B3	NDE1	Q9NXR1	651
PAFAH1B3	VAMP1	P23763	640
PAFAH1B3	PRR19	A6NJB7	629
PAFAH1B3	TMEM145	Q8NBT3	580
PAFAH1B3	CLK3	P49761	550
PAFAH1B3	ZNF574	Q6ZN55	525
PAFAH1B3	C6orf136	Q5SQH8	513
PAFAH1B3	LIPE	Q05469	511
PAFAH1B3	RABAC1	Q9UI14	494
PAFAH1B3	ZNF764	Q96H86	491
PAFAH1B3	VLDLR	P98155	484

IntAct

97 interactions, top by confidence:

A	B	Type	Score
PAFAH1B3	PAFAH1B3	psi-mi:“MI:0915”(physical association)	0.830
PAFAH1B3	LNX1	psi-mi:“MI:0915”(physical association)	0.770
PAFAH1B3	SDCBP2	psi-mi:“MI:0915”(physical association)	0.740
PAFAH1B2	PAFAH1B3	psi-mi:“MI:0915”(physical association)	0.740
PAFAH1B2	PAFAH1B1	psi-mi:“MI:0914”(association)	0.700
PAFAH1B3	PAFAH1B1	psi-mi:“MI:0915”(physical association)	0.640
PAFAH1B3	PAFAH1B1	psi-mi:“MI:0914”(association)	0.640
PAFAH1B3	FRD1	psi-mi:“MI:0915”(physical association)	0.560
FRD1	PAFAH1B3	psi-mi:“MI:0915”(physical association)	0.560
PAFAH1B3	NIF3L1	psi-mi:“MI:0915”(physical association)	0.560
PAFAH1B3	PICK1	psi-mi:“MI:0915”(physical association)	0.560
MEI4	PAFAH1B3	psi-mi:“MI:0915”(physical association)	0.560
PAFAH1B3	CHMP7	psi-mi:“MI:0915”(physical association)	0.550
CHMP7	PAFAH1B3	psi-mi:“MI:0915”(physical association)	0.550
VCAM1	PSMD11	psi-mi:“MI:0914”(association)	0.530
Pafah1b1	EDIL3	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (95): PAFAH1B3 (Two-hybrid), PAFAH1B3 (Affinity Capture-MS), PAFAH1B1 (Affinity Capture-MS), PAFAH1B3 (Two-hybrid), LNX1 (Two-hybrid), PAFAH1B3 (Two-hybrid), CHMP7 (Two-hybrid), SDCBP2 (Two-hybrid), C14orf166 (Co-fractionation), LNX1 (Affinity Capture-Western), VARS (Co-fractionation), PAFAH1B3 (Affinity Capture-MS), PAFAH1B3 (Two-hybrid), PAFAH1B3 (Affinity Capture-MS), PAFAH1B3 (Affinity Capture-MS)

ESM2 similar proteins: A0A5F8AH41, A2BIR6, A5WVX1, B4Q1B6, O35263, O35264, O43252, O54820, P34913, P40935, P52788, P56192, P68401, P68402, P76092, Q06AU9, Q09LX1, Q13057, Q15102, Q29460, Q2T9L8, Q32KX8, Q3SZ16, Q3SZA5, Q3URQ7, Q4WF29, Q5R4G2, Q5R6X1, Q5XJ57, Q5ZMS2, Q60967, Q61205, Q61206, Q63HM1, Q68FL6, Q68LP1, Q6JQN1, Q6PFX8, Q6Q2C2, Q711G3

Diamond homologs: O35263, O35264, P68401, P68402, Q15102, Q29460, Q5R4G2, Q5R6X1, Q5ZMS2, Q61205, Q61206, Q9VXP4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	35
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

892 predictions. Top by Δscore:

Variant	Effect	Δscore
19:42299943:T:TA	donor_gain	1.0000
19:42300088:ACAAT:A	acceptor_gain	1.0000
19:42300089:CAAT:C	acceptor_gain	1.0000
19:42300089:CAATC:C	acceptor_gain	1.0000
19:42300090:AAT:A	acceptor_gain	1.0000
19:42300090:AATCT:A	acceptor_loss	1.0000
19:42300091:AT:A	acceptor_gain	1.0000
19:42300091:ATCT:A	acceptor_loss	1.0000
19:42300092:TCT:T	acceptor_loss	1.0000
19:42300093:C:CC	acceptor_gain	1.0000
19:42300093:C:CG	acceptor_loss	1.0000
19:42300094:T:G	acceptor_loss	1.0000
19:42300095:G:C	acceptor_gain	1.0000
19:42300165:GCTCA:G	donor_loss	1.0000
19:42300166:CTCAC:C	donor_loss	1.0000
19:42300167:TCA:T	donor_loss	1.0000
19:42300168:CA:C	donor_loss	1.0000
19:42300169:A:C	donor_loss	1.0000
19:42302035:TGGTG:T	acceptor_gain	1.0000
19:42302036:GGTG:G	acceptor_gain	1.0000
19:42302037:GTG:G	acceptor_gain	1.0000
19:42302038:TG:T	acceptor_gain	1.0000
19:42302039:GCT:G	acceptor_loss	1.0000
19:42302040:C:CC	acceptor_gain	1.0000
19:42302230:A:AC	donor_gain	1.0000
19:42302231:C:CC	donor_gain	1.0000
19:42302263:T:TA	donor_gain	1.0000
19:42302500:GGAG:G	donor_gain	1.0000
19:42302501:GAG:G	donor_gain	1.0000
19:42302501:GAGG:G	donor_gain	1.0000

AlphaMissense

1494 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:42301984:C:T	G45E	0.999
19:42297191:G:C	H195D	0.998
19:42297199:T:A	D192V	0.998
19:42297200:C:G	D192H	0.998
19:42301984:C:A	G45V	0.998
19:42301985:C:A	G45W	0.998
19:42297198:A:C	D192E	0.997
19:42297198:A:T	D192E	0.997
19:42297199:T:G	D192A	0.997
19:42300063:G:C	N105K	0.997
19:42300063:G:T	N105K	0.997
19:42300073:C:A	G102V	0.997
19:42300208:C:G	R83P	0.997
19:42300244:C:T	G71D	0.997
19:42300282:C:A	W58C	0.997
19:42300282:C:G	W58C	0.997
19:42300284:A:G	W58R	0.997
19:42300284:A:T	W58R	0.997
19:42301981:T:A	D46V	0.997
19:42301990:A:G	F43S	0.997
19:42301993:A:T	V42D	0.997
19:42302243:A:G	W23R	0.997
19:42302243:A:T	W23R	0.997
19:42297189:A:C	H195Q	0.996
19:42297189:A:T	H195Q	0.996
19:42297220:A:T	I185N	0.996
19:42300074:C:G	G102R	0.996
19:42300082:A:T	V99D	0.996
19:42300175:G:T	P94H	0.996
19:42300233:C:G	D75H	0.996

dbSNP variants (sampled 300 via entrez): RS1000004409 (19:42299219 C>A,G,T), RS1000202339 (19:42299624 T>C), RS1001223847 (19:42299835 C>G,T), RS1001405277 (19:42302645 C>G), RS1001438052 (19:42299823 T>C,G), RS1001438251 (19:42303064 G>T), RS1001576546 (19:42304110 T>A), RS1001994172 (19:42304289 A>G), RS1002277888 (19:42301073 C>T), RS1002281246 (19:42304506 A>C,G), RS1002491495 (19:42301363 C>T), RS1002995846 (19:42297709 G>A), RS1003075628 (19:42304156 C>G,T), RS1003105362 (19:42304392 G>A), RS1003846967 (19:42302414 G>C)

Disease associations

OMIM: gene MIM:603074 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5108 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

57 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, affects binding, increases reaction	3
Valproic Acid	affects cotreatment, increases expression, increases methylation	3
methylmercuric chloride	increases expression	2
bisphenol A	affects expression, increases expression	2
cobaltous chloride	decreases expression	2
Benzo(a)pyrene	decreases methylation, increases expression	2
Cyclosporine	decreases expression	2
TAK-243	decreases sumoylation	1
pirinixic acid	affects binding, decreases expression, increases activity	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
deguelin	decreases expression	1
K 7174	decreases expression	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
nutlin 3	affects cotreatment, increases secretion	1
pyrachlostrobin	decreases expression	1
jinfukang	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2209088	Binding	Inhibition of PAFAH1B3 binding to FP-biotin in [12C][14N]-lysine, arginine and [13C6][15N2]-lysine, arginine labeled HEK293T cells at 20 uM after 1 hr by isotopic activity-based protein profiling-MudPIT assay	Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3D8	Abcam HEK293T PAFAH1B3 KO	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder